
Latest News
Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario
February 20, 2025
Apo-Teriparatide Injection ™ is a generic alternative to Forteo®.
Osteoporosis pharmacologic therapies are classified as antiresorptive therapy, which inhibits osteoclastic activity, and anabolic therapy, which stimulates new bone formation. Apo-Teriparatide is an anabolic therapy.
To view more information about provincial and territorial drug coverage visit https://osteoporosis.ca/provincial-territorial-drug-coverage/
OC MAKES THE NEWS – RECENT ITEMS
DENOZA® is now available in Canada
Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]
Healthcare Professional Educational Events
Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
